Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 30;127(3):488–499. doi: 10.1038/s41416-022-01823-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Cytotoxicity of the IAP inhibitor BV6 in a panel of 17 ovarian cancer (OC) cell lines (CLs). b BRCA1-mutated OC CLs (BRCA1-MUT) are on average more sensitive to BV6 than BRCA1 wild-type (BRCA1-WT) OC CLs. c Cytotoxicity of the IAP inhibitor LCL161 in a panel of 17 OC CLs. d BRCA1-mutated OC CLs are on average more sensitive to LCL161 than BRCA1 wild-type OC CLs. e After the silencing of XIAP, using 25 nM siRNA (siXIAP), the proliferation of the BRCA1-mutated OC CL UWB1289 is downregulated in comparison to the BRCA1-restored OC CL UWB1289-BRCA1. These data were normalised to the proliferation of the same CLs after treatment with a control scrambled siRNA. f Evaluation of the level of apoptosis after treatment with BV6 (_B) and LCL161 (_L). Apoptosis is shown as a percentage increase of that in corresponding control-untreated CLs (n = 3). Note: BRCA1-mutated OC CLs are highlighted with a pattern, the BRCA1-methylated OC CL is highlighted with oblique banding, the BRCA1-restored OC CL is highlighted with horizontal banding and BRCA1 wild-type OC CLs are highlighted in white in the bar graphs.